MedPage Today December 12, 2024
Shannon Firth

— Patent thickets another key target

Policy experts punched holes in drug companies’ claims that the Medicare Drug Price Negotiation Program will stunt innovation and weighed in on other drug price-curbing strategies during a webinar hosted by the National Institute for Health Care Management (NIHCM) Foundation on Wednesday.

The Backlash to Medicare Drug Price Negotiation

A number of pharmaceutical companies and other stakeholders have fought the drug price negotiation program in courts, with some arguing that the program will stifle innovation and reduce access to drugs for vulnerable patients.

However, Gregg Girvan, MPP, a fellow for the Foundation for Research on Equal Opportunity (FREOPP), said the policy won’t be nearly as damaging to innovation as pharmaceutical companies have warned.

Girvan...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Insurance, Medicare, Pharma, Pharma / Biotech
Related Articles:
CMS Launches New Program for Mental Health, OUD Treatment
How Medicare Negotiated Drug Prices Compare to Other Countries
Telehealth groups call for urgent action as Medicare flexibility deadline looms
Innovating Without Compromising Integration: Considerations For Medicare
How the Federal Government Could Push People Toward Medicare Advantage – And Replace Traditional Medicare

Share This Article